Medicare GLP‑1 relief
Big cost change in the U.S.: Medicare Part D caps out‑of‑pocket drug costs at $2,100 for 2026, and a new GLP‑1 Bridge program starts July 1 offering Wegovy access at a $50 monthly copay. This could materially change annual affordability for people using GLP‑1s for weight and type‑2 diabetes management. (medium.com)
CMS set the 2026 Part D annual out‑of‑pocket threshold by indexing the prior year’s cap to the annual percentage increase in average Part D drug expenditures, rather than choosing an ad‑hoc number. (cms.gov) CMS will run a short‑term Medicare GLP‑1 Bridge demonstration that operates outside the normal Part D coverage and payment flow from July 1 through December 31, 2026. (cms.gov) The Bridge will cover GLP‑1 products approved for weight reduction, naming Wegovy (semaglutide) and Zepbound (tirzepatide), and eligibility is defined by BMI thresholds and specified clinical criteria. (kff.org) CMS says the Bridge’s cost‑sharing for eligible beneficiaries will be uniform across benefit phases, meaning the copay won’t vary depending on whether a fill occurs in deductible, initial coverage, or catastrophic phases. (cms.gov) Operationally, the Bridge will use a single central processor to handle prior authorization, claims adjudication and pharmacy payments, and Part D sponsors will not bear financial risk for drugs dispensed under the Bridge. (cms.gov) The Bridge is explicitly designed as an interim pathway into the BALANCE Model, which is slated to start January 1, 2027; Part D sponsors must apply and be approved to join BALANCE, with CMS signaling a March 2026 release of participation/application details. (cms.gov) Advocates and analysts warned the redesigned Part D structure means many high‑utilizer beneficiaries could reach the new out‑of‑pocket threshold early in the year — some estimates name millions doing so within months — and CMS has published 2026 guidance materials for beneficiaries explaining the change. (savingadvice.com)
